(News Bulletin 247) – AstraZeneca will present new data on its portfolio of vaccines and immune therapies at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 15 to 18, 2023. The laboratory will take the opportunity to present about fifteen summaries.
AstraZeneca will notably present studies on AZD3152, AstraZeneca’s long-acting experimental COVID-19 antibody, but also on Evusheld (tixagevimab and cilgavimab) and Vaxzevria in COVID-19 or on Beyfortus (nirsevimab ) in respiratory syncytial virus (RSV).
Additional data on AstraZeneca’s growing portfolio of vaccines and immunotherapies against a variety of pathogens will also be presented.
‘We are delighted to share our data at ECCMID this year, reflecting the progress of our portfolio of vaccines and immune therapies and our ambition to provide long-lasting immunity and protection against infectious diseases that affect millions of people around the world. world,” commented Iskra Reic, executive vice president of vaccines and immune therapies at AstraZeneca.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
